Moreover, we recently found that CRMP is sufficient to reduce dyslipidemia, hepatic steatosis, and hepatic insulin resistance in spontaneously obese non‐human primates due to subtle sustained increases in hepatic mitochondrial oxidation (Goedeke et al., 2019). Here, INS is linked to fatty liver disease.